Status:
TERMINATED
The Effect of QVAR on Lung Functioning in Chronic Obstructive Pulmonary Disease
Lead Sponsor:
National Jewish Health
Conditions:
COPD
Eligibility:
All Genders
45+ years
Phase:
NA
Brief Summary
This is an investigator-sponsored research study to evaluate if treatment with HFA-134a beclomethasone (QVAR) has an effect on peripheral (or outer) airway inflammation and airway "remodeling" or scar...
Eligibility Criteria
Inclusion
- COPD diagnosis
- FEV1/FVC\<70%
- FEV1 50-80% predicted
- Albuterol response of \<12% and \<200mL or methacholine PC20 \> 8mg/mL
- RV \> 120% predicted
- DLCO \< 80%
- smokers and nonsmokers
- Lower age limit 45 years
Exclusion
- Asthma
- Other chronic airway or parenchymal lung disease
- Other comorbid illness (including but not limited to DM, MI or CAD-related intervention in 6 months, neurologic disease, syncope)
- Use of any steroid (oral, IV, nasal, pulmonary) within 12 weeks
- Use of theophylline, leukotriene modifiers within 12 weeks
- Use of long-acting beta-agonists (formoterol, salmeterol) or anticholinergic (tiotropium)
Key Trial Info
Start Date :
November 1 1999
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2005
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00238082
Start Date
November 1 1999
End Date
February 1 2005
Last Update
March 29 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Jewish Medical and Research Center
Denver, Colorado, United States, 80206